MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
30 oct. 2023 06h15 HE
|
MannKind
Patent covers compositions of clofazimine, and methods for treating lung infectionsDevelopment of MNKD-101 (inhaled clofazimine) continues for the potential treatment of nontuberculous mycobacterial...
MannKind Corporation Announces Participation at Upcoming Conferences
05 sept. 2023 06h00 HE
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation Reports 2023 Second Quarter Financial Results
07 août 2023 16h00 HE
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 20232Q 2023 Endocrine Business Unit net revenues...
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
01 août 2023 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
31 juil. 2023 16h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 second quarter financial results and year to date financial...
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
22 juin 2023 06h05 HE
|
MannKind
Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)Time-in-range during waking...
Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
11 juin 2023 08h05 HE
|
MannKind
DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides...
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
24 mai 2023 08h30 HE
|
MannKind
DANBURY, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for...
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
10 mai 2023 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
09 mai 2023 20h21 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the...